|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-2-23
|
|
pubmed:abstractText |
A series of N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides targeting c-Met and VEGFR2 tyrosine kinases was designed and synthesized. The compounds were potent against these two enzymes with IC(50) values in the low nanomolar range in vitro, possessed favorable pharmacokinetic profiles and showed high efficacy in vivo in several human tumor xenograft models in mice.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1464-3405
|
|
pubmed:author |
pubmed-author:BeaulieuCaroleC,
pubmed-author:BeaulieuNormandN,
pubmed-author:BestermanJeffreyJ,
pubmed-author:ClaridgeStephenS,
pubmed-author:DézielRobertR,
pubmed-author:DubayMarjaM,
pubmed-author:DupontIsabelleI,
pubmed-author:GaudetteFrédéricF,
pubmed-author:GrangerMarie-ClaudeMC,
pubmed-author:IsakovicLjubomirL,
pubmed-author:LefebvreSylvainS,
pubmed-author:MannionMichaelM,
pubmed-author:NguyenHannahH,
pubmed-author:RaeppelFranckF,
pubmed-author:RaeppelStéphaneS,
pubmed-author:RahilJubrailJ,
pubmed-author:Robert MacleodAA,
pubmed-author:RobertMarie-FranceMF,
pubmed-author:SaavedraOscarO,
pubmed-author:Ste-CroixHélèneH,
pubmed-author:VaisburgArkadiiA,
pubmed-author:WangJamesJ,
pubmed-author:ZhanLijieL,
pubmed-author:ZhouNancyN
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1323-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19211249-Amides,
pubmed-meshheading:19211249-Animals,
pubmed-meshheading:19211249-Cell Line, Tumor,
pubmed-meshheading:19211249-HCT116 Cells,
pubmed-meshheading:19211249-Humans,
pubmed-meshheading:19211249-Imidazolidines,
pubmed-meshheading:19211249-Mice,
pubmed-meshheading:19211249-Protein Kinase Inhibitors,
pubmed-meshheading:19211249-Proto-Oncogene Proteins c-met,
pubmed-meshheading:19211249-Rats,
pubmed-meshheading:19211249-Receptor Protein-Tyrosine Kinases,
pubmed-meshheading:19211249-Vascular Endothelial Growth Factor Receptor-2,
pubmed-meshheading:19211249-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, MethylGene Inc., 7220 rue Frederick-Banting, Montréal, QC, Canada H4S 2A1.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
